ReviewCell death discovery2026
Placenta models for HIV-1-ART-nicotine comorbidity research: advances and remaining challenges.
Review in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Worldwide implementation of antiretroviral therapy (ART) for pregnant women living with human immunodeficiency virus type-1 (HIV-1) has markedly reduced mother-to-child HIV-1 transmission rate to less than one percent. Despite this benefit, adverse pregnancy outcomes remain a major concern. Placental deficits induced by antiretroviral drugs (ARVs) are increasingly recognized as a potential causative factor. Additionally, comorbid effects of substance use on placenta cannot be overstated. Addictive substances are commonly used by people living with HIV-1 (PLWH). However, globally, nicotine exposure through smoking or tobacco use remains a major comorbidity in PLWH. Yet, to date, whether and how, HIV-1, ARVs, and nicotine together exacerbate adverse effects on placenta and affect birth outcomes is unknown. Due to ethical concerns and impracticality of obtaining placenta tissues at different stages of pregnancy, appropriate experimental models that closely recapitulate in vivo placenta physiology are essential to define how HIV-1, ART, and nicotine independently or collectively affect placental development and functions. Herein, we provide a comprehensive review of the experimental placenta models that have been or are yet to be utilized to study placental comorbid pathobiology induced by HIV-1 infection, ART, and/or nicotine exposure. We emphasize how each model is used (or underused) to interrogate infection biology, pharmacokinetic profile, and toxico-pharmacologic mechanisms. Moreover, key limitations associated with each placenta model and necessary improvements for investigating HIV-1 and associated comorbidity are highlighted. Overall, this review seeks to educate both clinical and basic scientists on advances made, and remaining challenges in understanding comorbid effects of HIV-1-ART-nicotine on pregnancy outcomes using experimental placenta models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.